Amgen: Cost Cutting, Buybacks and No Split

Amgen’s (AMGN) earnings yesterday looked solid but analysts kept saying the real news would come at today’s “business review.” So far, that news appears to be good. RBC Capital Markets’ Michael Yee and team explain: Reuters [The key] incremental takeaways from mgmt comments at analyst day consistent with our positive thesis… CEO does not see [...]